Table V.
Association between clinical factors and epidermal growth factor receptor mutation status in exon 19 and 21.
| Characteristics | Exon 19 mutation, n (%) (n=33) | Exon 21 mutation, n (%) (n=40) | P-value |
|---|---|---|---|
| Age, years | |||
| ≤60 | 17 (51.5) | 19 (47.5) | 0.816 |
| >60 | 16 (48.5) | 21 (52.5) | |
| Sex | 0.876 | ||
| Male | 20 (60.6) | 19 (47.5) | |
| Female | 13 (39.4) | 21 (52.5) | |
| Smoking status | 0.805 | ||
| Never smoked | 26 (78.8) | 31 (77.5) | |
| Regular smoker | 7 (21.2) | 7 (17.5) | |
| Ex-smoker | 0 (0.0) | 2 (5.0) | |
| AJCC stage | 0.880 | ||
| I | 1 (3.0) | 2 (5.0) | |
| II | 2 (6.1) | 2 (5.0) | |
| III | 3 (9.1) | 2 (5.0) | |
| IV | 27 (81.8) | 34 (85.0) | |
| Histology type | 0.268 | ||
| Squamous cell carcinoma | 1 (3.0) | 0 (0.0) | |
| Adenocarcinoma | 32 (97.0) | 40 (100.0) | |
| Median SUVmax, primary lesion | 10.6 | 8.7 | 0.021 |
| SUVmax range, primary lesion | 7.2-12.7 | 5.0-10.2 | 0.057 |
| SUVmax≤5 | 4 (28.6) | 10 (71.4) | |
| 5<SUVmax≤10 | 12 (40.0) | 18 (60.0) | |
| 10<SUVmax≤15 | 14 (53.8) | 12 (46.2) | |
| SUVmax>15 | 3 (100.0) | 0 (0.0) | |
| Median SUVmax, metastatic lymph nodes | 6.7 (3.6-8.3) | 6.9 (4.0-9.5) | 0.960 |
| SUVmax range, metastatic lymph nodes | 0.920 | ||
| SUVmax≤5 | 11 (45.8) | 13 (54.2) | |
| 5<SUVmax≤10 | 15 (40.5) | 22 (59.5) | |
| SUVmax>10 | 3 (42.9) | 4 (57.1) | |
| Median CEA, ng/ml | 22.5 | 24.9 | 0.771 |
| CEA range, ng/ml | 5.6-53.0 | 4.5-91.2 | 0.780 |
| CEA≤5 | 8 (40.0) | 12 (60.0) | |
| 5<CEA≤10 | 6 (60.0) | 4 (40.0) | |
| 10<CEA≤15 | 5 (45.5) | 6 (54.5) | |
| CEA>15 | 14 (45.2) | 17 (54.8) |
SD, standard deviation; n, number; AJCC, American Joint Committee on Cancer; SUVmax, maximum standardized uptake value; CEA, carcinoembryonic antigen.